Clinical impact of pathology reviews of outside material: A patient-focused approach

Journal of Clinical Oncology

Volumn 29, Issue 31, 2011, Pages 4212-4213

  Banerjee, Diponkar ^a   Gascoyne, Randy D ^a   Slack, Graham ^a   Hayes, Malcolm ^a   Sehn, Laurie H ^a   Connors, Joseph M ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LETTER; PRIORITY JOURNAL;

FEMALE; HODGKIN DISEASE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MEDICAL ONCOLOGY; PATHOLOGY; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 80755155686     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.4255     Document Type: Letter

References (3)

1. Smith LB: Pathology review of outside material: When does it help and when can it hurt? J Clin Oncol 29:2724-2727, 2011
2. Jaffe ES: The 2008 WHO classification of lymphomas: Implications for clinical practice and translational research. Hematology Am Soc Hematology Educ Program 523-531, 2009
3. BC Cancer Agency: Treatment of Lymphoma, Chronic Lymphocytic Leukemia and Plasma Cell Disorders Including Myeloma, as recommended by the British Columbia Cancer Agency. http://www.bccancer.bc.ca/HPI/Cancer ManagementGuidelines/ Lymphoma/default.htm